Pancreatitis in Patients Receiving Tirzepatide (Mounjaro): A One-Year Audit in a UK District General Hospital

In this single-centre audit, pancreatitis in patients receiving tirzepatide was rare, mild, and commonly associated with other aetiologies, such as gallstones or alcohol. No cases of chronic pancreatitis occurred among tirzepatide users. Although causality cannot be established, the overall risk appears low. Clinicians should remain vigilant during early treatment phases when weight loss is greatest. Further multicentre studies with prescribing denominator data are warranted to clarify incidence and potential preventive measures, such as short-term ursodeoxycholic acid prophylaxis in high-risk individuals.